Plexiform neurofibroma genesis: Questions of Nf1 gene dose and hyperactive mast cells

Karl Staser, Feng Chun Yang, D. Clapp

Research output: Contribution to journalArticle

25 Citations (Scopus)


Purpose of review: Tumorigenic cells can co-opt normal functions of nonmalignant hematopoietic cells, promoting tumor progression. Recent mouse and human studies indicate that mast cells underpin inflammation in the plexiform neurofibroma microenvironment of neurofibromatosis type 1. In this model, Nf1 homozygous-deficient Schwann cells recruit hyperactive mast cells, promoting tumorigenesis. Here, we discuss the importance of Nf1 gene dosage, delineate hematopoietic contributions to the plexiform neurofibroma microenvironment, and highlight applications to human treatment. Recent findings: Previous studies found that plexiform neurofibroma formation in a mouse model requires biallelic loss of Nf1 in Schwann cells and an Nf1 heterozygous cellular background. Now, transplantation and pharmacological experiments have indicated that tumor formation specifically requires Nf1 heterozygosity of c-kit-dependent bone marrow. Summary: Neurofibromatosis type 1 results from autosomal dominant mutations of the NF1 tumor suppressor gene. Although unpredictable second-hit mutations in the remaining NF1 allele precede local manifestations such as tumor formation, human and mouse data indicate that NF1/Nf1 gene haploinsufficiency modulates cellular physiology and disease pathogeneses. In particular, Nf1 haploinsufficient mast cells demonstrate multiple gain-in-functions, and mast cells permeate neurofibroma tissue. Transplantation experiments have shown that these aberrant mast cells critically underpin the tumor microenvironment. Using these findings, clinicians have medically treated a patient with a debilitating plexiform neurofibroma.

Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalCurrent Opinion in Hematology
Issue number4
StatePublished - 2010


Neurofibromatosis 1 Genes
Plexiform Neurofibroma
Mast Cells
Neurofibromatosis 1
Schwann Cells
Tumor Microenvironment
Gene Dosage
Tumor Suppressor Genes
Bone Marrow


  • c-kit
  • mast cells
  • neurofibroma
  • neurofibromatosis type 1
  • tumor microenvironment

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Plexiform neurofibroma genesis : Questions of Nf1 gene dose and hyperactive mast cells. / Staser, Karl; Yang, Feng Chun; Clapp, D.

In: Current Opinion in Hematology, Vol. 17, No. 4, 2010, p. 287-293.

Research output: Contribution to journalArticle

title = "Plexiform neurofibroma genesis: Questions of Nf1 gene dose and hyperactive mast cells",
abstract = "Lippincott Williams & Wilkins.",
keywords = "c-kit, mast cells, neurofibroma, neurofibromatosis type 1, tumor microenvironment",
author = "Karl Staser and Yang, {Feng Chun} and D. Clapp",
year = "2010",
doi = "10.1097/MOH.0b013e328339511b",
language = "English",
volume = "17",
pages = "287--293",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "4",



T1 - Plexiform neurofibroma genesis

T2 - Questions of Nf1 gene dose and hyperactive mast cells

AU - Staser, Karl

AU - Yang, Feng Chun

AU - Clapp, D.

PY - 2010

Y1 - 2010

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - c-kit

KW - mast cells

KW - neurofibroma

KW - neurofibromatosis type 1

KW - tumor microenvironment

UR -

UR -

U2 - 10.1097/MOH.0b013e328339511b

DO - 10.1097/MOH.0b013e328339511b

M3 - Article

C2 - 20571392

AN - SCOPUS:77954072798

VL - 17

SP - 287

EP - 293

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 4

ER -